XNAS · Healthcare · Biotechnology
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
Scinai remains a micro-cap biotech with no meaningful catalyst, and H1 revenue of **$949k** is still far too small to offset a **$0.64** loss per share. The explosive growth rate is just a base-effect anomaly; profitability and execution remain weak.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-24 | H1 2026 | — | -0.64 | — | $949,000 | — | -3.73% | -20.13% | — |
| 2026-04-01 | FY 2025 | — | -3.56 | — | $1.3M | — | +1.40% | -9.25% | +11.09% |
| 2024-11-22 |
| Q3 2024 |
| — |
| -8.40 |
| — |
| $168,000 |
| — |
| -0.28% |
| -2.82% |
| -5.37% |
| 2024-08-15 | Q2 2024 | — | -4.00 | — | $284,000 | — | +2.92% | +6.37% | -10.88% |
| 2024-07-02 | Q1 2024 | — | -4.00 | — | $0 | — | +4.87% | -2.01% | +39.60% |
| 2024-05-15 | Q4 2023 | — | -8.00 | — | $0 | — | +2.27% | -21.82% | -20.68% |
| 2023-08-11 | Q2 2023 | -0.91 | -1.20 | -31.87% | $0 | ❌ Miss | — | — | -2.23% |
| 2023-05-15 | Q1 2023 | -0.73 | -1.20 | -64.38% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.